Clinical outcomes of advanced-stage glassy cell carcinoma of the uterine cervix: A need for reappraisal

Nara Yoon, Ji Ye Kim, Hyunsoo Kim

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We performed a retrospective analysis of the clinical features and patient outcomes for advanced-stage glassy cell carcinoma of the uterine cervix. The study was restricted to cases in which the glassy cell features constituted at least 95% of the biopsied specimen. During the study period, 675 patients were diagnosed with primary cervical carcinoma. Five (0.7%) of the 675 patients had cervical glassy cell carcinoma; of these, three were premenopausal, and two were postmenopausal. Abnormal vaginal bleeding was the most frequent presenting symptom. Glassy cell carcinoma presented as a fungating, exophytic, or infiltrative mass. The greatest tumor dimension ranged from 3 to 9 cm. All patients had parametrial extension. Four patients had stage IIB tumors, and one had a stage IIIB tumor. All patients received concurrent chemoradiation therapy. The patient with a stage IIIB tumor died of hypovolemic shock caused by upper gastrointestinal bleeding during radiation therapy. Three patients with stage IIB tumors survived for more than 8 years without tumor recurrence or metastasis. One of these three patients died of pelvic recurrence 10 years after the initial diagnosis. Cervical glassy cell carcinoma has traditionally been considered an aggressive, highly malignant tumor with poor prognosis, but our data suggest that patient survival is not significantly decreased compared with other histological types of cervical carcinoma. It will be necessary to analyze patient outcomes using a larger number of cervical glassy cell carcinoma cases to confirm our findings.

Original languageEnglish
Pages (from-to)78448-78454
Number of pages7
JournalOncotarget
Volume7
Issue number48
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Cervix Uteri
Carcinoma
Neoplasms
Glassy cell carcinoma of the cervix
Recurrence
Uterine Hemorrhage
Shock
Radiotherapy
Hemorrhage
Neoplasm Metastasis
Survival

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

@article{08b5e5961239493bb1ee2954c419bb78,
title = "Clinical outcomes of advanced-stage glassy cell carcinoma of the uterine cervix: A need for reappraisal",
abstract = "We performed a retrospective analysis of the clinical features and patient outcomes for advanced-stage glassy cell carcinoma of the uterine cervix. The study was restricted to cases in which the glassy cell features constituted at least 95{\%} of the biopsied specimen. During the study period, 675 patients were diagnosed with primary cervical carcinoma. Five (0.7{\%}) of the 675 patients had cervical glassy cell carcinoma; of these, three were premenopausal, and two were postmenopausal. Abnormal vaginal bleeding was the most frequent presenting symptom. Glassy cell carcinoma presented as a fungating, exophytic, or infiltrative mass. The greatest tumor dimension ranged from 3 to 9 cm. All patients had parametrial extension. Four patients had stage IIB tumors, and one had a stage IIIB tumor. All patients received concurrent chemoradiation therapy. The patient with a stage IIIB tumor died of hypovolemic shock caused by upper gastrointestinal bleeding during radiation therapy. Three patients with stage IIB tumors survived for more than 8 years without tumor recurrence or metastasis. One of these three patients died of pelvic recurrence 10 years after the initial diagnosis. Cervical glassy cell carcinoma has traditionally been considered an aggressive, highly malignant tumor with poor prognosis, but our data suggest that patient survival is not significantly decreased compared with other histological types of cervical carcinoma. It will be necessary to analyze patient outcomes using a larger number of cervical glassy cell carcinoma cases to confirm our findings.",
author = "Nara Yoon and Kim, {Ji Ye} and Hyunsoo Kim",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.12905",
language = "English",
volume = "7",
pages = "78448--78454",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "48",

}

Clinical outcomes of advanced-stage glassy cell carcinoma of the uterine cervix : A need for reappraisal. / Yoon, Nara; Kim, Ji Ye; Kim, Hyunsoo.

In: Oncotarget, Vol. 7, No. 48, 01.01.2016, p. 78448-78454.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical outcomes of advanced-stage glassy cell carcinoma of the uterine cervix

T2 - A need for reappraisal

AU - Yoon, Nara

AU - Kim, Ji Ye

AU - Kim, Hyunsoo

PY - 2016/1/1

Y1 - 2016/1/1

N2 - We performed a retrospective analysis of the clinical features and patient outcomes for advanced-stage glassy cell carcinoma of the uterine cervix. The study was restricted to cases in which the glassy cell features constituted at least 95% of the biopsied specimen. During the study period, 675 patients were diagnosed with primary cervical carcinoma. Five (0.7%) of the 675 patients had cervical glassy cell carcinoma; of these, three were premenopausal, and two were postmenopausal. Abnormal vaginal bleeding was the most frequent presenting symptom. Glassy cell carcinoma presented as a fungating, exophytic, or infiltrative mass. The greatest tumor dimension ranged from 3 to 9 cm. All patients had parametrial extension. Four patients had stage IIB tumors, and one had a stage IIIB tumor. All patients received concurrent chemoradiation therapy. The patient with a stage IIIB tumor died of hypovolemic shock caused by upper gastrointestinal bleeding during radiation therapy. Three patients with stage IIB tumors survived for more than 8 years without tumor recurrence or metastasis. One of these three patients died of pelvic recurrence 10 years after the initial diagnosis. Cervical glassy cell carcinoma has traditionally been considered an aggressive, highly malignant tumor with poor prognosis, but our data suggest that patient survival is not significantly decreased compared with other histological types of cervical carcinoma. It will be necessary to analyze patient outcomes using a larger number of cervical glassy cell carcinoma cases to confirm our findings.

AB - We performed a retrospective analysis of the clinical features and patient outcomes for advanced-stage glassy cell carcinoma of the uterine cervix. The study was restricted to cases in which the glassy cell features constituted at least 95% of the biopsied specimen. During the study period, 675 patients were diagnosed with primary cervical carcinoma. Five (0.7%) of the 675 patients had cervical glassy cell carcinoma; of these, three were premenopausal, and two were postmenopausal. Abnormal vaginal bleeding was the most frequent presenting symptom. Glassy cell carcinoma presented as a fungating, exophytic, or infiltrative mass. The greatest tumor dimension ranged from 3 to 9 cm. All patients had parametrial extension. Four patients had stage IIB tumors, and one had a stage IIIB tumor. All patients received concurrent chemoradiation therapy. The patient with a stage IIIB tumor died of hypovolemic shock caused by upper gastrointestinal bleeding during radiation therapy. Three patients with stage IIB tumors survived for more than 8 years without tumor recurrence or metastasis. One of these three patients died of pelvic recurrence 10 years after the initial diagnosis. Cervical glassy cell carcinoma has traditionally been considered an aggressive, highly malignant tumor with poor prognosis, but our data suggest that patient survival is not significantly decreased compared with other histological types of cervical carcinoma. It will be necessary to analyze patient outcomes using a larger number of cervical glassy cell carcinoma cases to confirm our findings.

UR - http://www.scopus.com/inward/record.url?scp=84998693450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84998693450&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.12905

DO - 10.18632/oncotarget.12905

M3 - Article

C2 - 27793022

AN - SCOPUS:84998693450

VL - 7

SP - 78448

EP - 78454

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 48

ER -